How an ‘Impossible’ Idea Led to a Pancreatic Cancer Breakthrough

Pancreatic cancer has long been one of the deadliest diagnoses, with few effective treatments and a five-year survival rate of just 3% for metastatic cases. However, a new drug, daraxonrasib, developed by Revolution Medicines, is poised to change that by targeting the KRAS protein, which drives nearly all pancreatic tumors as well as many lung and colon cancers. The KRAS protein was long considered untargetable, described as a 'greasy ball' resistant to drugs. But researchers at institutions like the University of North Carolina and the University of Michigan, supported by the National Institutes of Health and the Howard Hughes Medical Institute, persisted. Industry later refined the approach, creating a molecule that binds to and disables KRAS. Daraxonrasib has been fast-tracked by the FDA and could win approval later this year, with early access already available to some patients. In late-stage trials, it showed effectiveness in patients with metastatic pancreatic cancer who had exhausted chemotherapy options. While not a cure, it offers a significant improvement over existing treatments, with patients taking three pills daily. The drug’s success has spurred multiple companies to develop similar KRAS-targeting treatments for pancreatic, lung, and colon cancers. However, side effects like rash, diarrhea, fatigue, and severe skin reactions remain challenges. For now, daraxonrasib provides new hope for patients facing a disease that kills over 50,000 Americans annually.